Centner Academy, the first happiness school in the U.S., will offer three schooling options when it reopens its school campuses for students in Preschool to 8th grade on September 8, 2020.
We believe children should have the opportunity to be together, to bond and connect — especially now with the uncertainty of our current times.
Centner Academy learns from public health officials and local doctors, and participates in national and international forums that bring them the latest research and findings from schools that have reopened around the world.
The three options for students’ learning paths in the 2020-2021 school year include:
- In-person classes: full year in person (transition to virtual if required by local restrictions).
- Half-year option: September-December 2020 online; January-June 2021 in person.
- Online only classes: full year online.
During the first week of school, Centner Academy will be implementing a retreat-style learning method, both in-person and online, where the focus will be on students learning the school culture through team-building activities as opposed to just reviewing school rules.
Centner Academy is currently hiring teachers and its intensive 5-week Professional Development begins Monday, August 3rd. Teachers will undergo a cumulative 10,000 hours of engaging, interactive development. Hands-on training will focus on mindfulness in the classroom, project-based learning, conscious discipline, emotional intelligence, social entrepreneurship, neuroleadership and executive function, subject area curriculum, and more.
“At Centner Academy, we’re striving for every child to start school happy and excited for the rest of the year,” said Leila Centner, Founder & CEO of Centner Academy. “A positive school climate and culture promotes students’ ability to learn and succeed in life. Our goal is to transform the heart of education to ensure happy, confident, compassionate, mindful, empathic and connected children through a more holistic approach to teaching that responds to social challenges.”
In preparation for back to school, Centner Academy will follow all legal requirements and implement new safety and sanitation precautions, processes and policies for the health and physical well-being of children, teachers and staff while on campus, including:
- Facility modifications, such as the installation of Germicidal Ultraviolet Lights inside HVAC systems located in all classrooms, bathrooms and elevators, to destroy harmful microorganisms, including mold, mildew, fungi, bacteria, and viruses like COVID-19, eliminate bad odors, and purify the air; as well as the installation of electrostatic air purifiers in common areas to remove contaminants from the air and improve air quality; and re-equipment of all HVAC systems with advanced filters to mechanically purify the air.
- Enhanced cleaning training and routines: All faculty, staff, and students will have training on hygiene requirements and cleaning practices, and cleaning crews will be doing hourly sanitization of surfaces and nightly deep cleaning and sanitizing.
- Temperature screenings: The school asks that all parents screen their child’s temperature before coming to school, and will do temperature checks upon arrival for all visitors with thermal cameras and no-touch sensors.
- Stay home requirements: The school’s sick policy has been updated to include a required stay-home clause for any individual who is feeling unwell, with at least 48 hours of being symptom-free before returning to school (this includes students, visitors, faculty and staff).
- Small class sizes: Centner Academy boasts small classes sizes as a normal part of the student experience and will continue to look to research and science to inform the safest class size, both for student health and social-emotional wellness.
- No large group gatherings: Students will eat in their classrooms rather than in a large cafeteria space limit large group sizes.
- Indoor shoes: All students will remove their outdoor shoes at school and wear indoor shoes instead, reducing the possibility for outdoor contaminants to enter the building.
- Anti-bullying software in school computers: Centner Academy is installing STOPit, an award-winning software platform that mitigates, deters and controls inappropriate conduct in schools and allows students to report inappropriate behavior anonymously via mobile app, web, or phone hotline service.
- Water and other shared services: Students will be asked to bring reusable water bottles from home (or can purchase one from the school store). The school is investing in filtered water bottle filling stations throughout both school buildings and will prevent the use of water fountains in some phases of reopening. The number of students using each restroom will be limited.
- Social-emotional wellbeing: the school’s commitment to embedding mindfulness across the curriculum and supporting the grit, resilience, and social-emotional wellbeing of students will continue to be a priority. The school’s schedules will still include dedicated time to mindfulness, as well as having the principles of mindful education embedded in all subjects, whether they are taught online or in-person.
“We are committed to reassessing these policies and procedures frequently, increasing and reducing restrictions as needed to keep our community safe, happy and strong,” stated Leila Centner.
Flavor Enhancers Market To Reach USD 11.5 Billion By 2027 | Reports and Data
New York, Aug. 12, 2020 (GLOBE NEWSWIRE) — According to the analysis of Reports and Data, the Global Flavor Enhancers Market was valued at USD 6.6 billion in 2019 and is expected to reach USD 11.5 billion by the year 2027, growing at a CAGR of around 6.5%. According to the Food and Drug Administration (FDA), flavor enhancers are the substances that have no pronounced flavor or taste of their own but which bring out and improve the flavors in the foods to which they are added. The term flavor potentiator has also been used with the same meaning. The most commonly used substances in this category are monosodium L-glutamate (MSG), disodium 5′-inosinate (IMP), and disodium 5′-guanylate (GMP).
The growth of the segment is driven by the expansion of the global beverage industry, an increase in demand for convenience food, changing consumer lifestyle, and an increase in the number of sensory-oriented consumers worldwide. The global flavor enhancers market is expected to witness an upsurge owing to the introduction of new food products with natural ingredients and coloring pigments. Furthermore, technological advancements, growing demand for clean label products, and stringent regulations on synthetic enhancers are influencing manufacturers to incorporate more natural flavors in their offerings. Increasing the use of natural flavor enhancers by the food processing industry is a key factor driving the flavor enhancers market’s growth.
However, factors such as mounting raw material prices and high entry barriers and price pressure on manufacturers due to consolidation affect the industry’s growth. Major trends prevailing in the market are consolidation in the industry, demand for substitutes for artificial flavor enhancers, the emergence of biotech flavor enhancers, and sensory trend.
The global flavor enhancers market is segregated based on type glutamates, acidulants, hydrolyzed vegetable protein, yeast extracts, and others (sweetness enhancers and nucleotides). Based on form, the global flavor enhancers market is segmented in Powder and Liquid & Semi-Liquid. Based on source, the market is segmented into natural and synthetic. Based on application, the market is bifurcated into processed & convenience foods, meat & fish products, beverages, and others (confectionery products, bakery, dairy, and condiments).
Get FREE Sample Copy with TOC of the Report to understand the structure of the complete report@ https://www.reportsanddata.com/sample-enquiry-form/3408
Further key findings from the report suggest
- By type, the glutamates segment was valued at USD 1.36 billion in 2019. Asia is the largest producer of glutamates, including MSG, accounting for approximately 93% of the global MSG production capacity. Greater demand, an economic and abundant workforce, and its use in processed foods are the prime reasons behind its significant production in Asia. Indonesia, China, Taiwan, Thailand, and Malaysia are the major glutamate manufacturers. China is one of the top manufacturers (66%), the consumer (51%), and exporter (49%) of MSG worldwide. Indonesia is the second-largest (15%) exporter of glutamates. The FDA reported that the Middle East and Africa consumed 4%, Europe 3%, North America 2%, and central and South America 2% MSG.
- Among the application segments, processed & convenience foods occupied a significant share of about 38.3% in the flavor enhancers market. Flavor enhancers like lactic acid find extensive application in the processed & convenience food industry as it benefits from regulating microflora in the food and acting as preservatives. It is formed by the natural fermentation process in food products such as pickled vegetables, cheese, and soy sauce.
- Among the source segments, the natural segment leis growing at a rapid CAGR of 6.8%. The snowballing health awareness among the population and the rising demand for organic foods and upsurge in the buying power of the population fosters the market growth. Offering unique and tastier flavor enhancers would principally boost the demand in the global natural food flavor enhancers market.
- By form, the liquid segment is projected to grow at the fastest CAGR 6.5% during the analysis period. Factors such as minimized ingredient loss, high consistency and uniformity, specification-oriented superior quality production, and excellent microbiological safety drive the market.
- North America occupied a share market share of about 33.5% in 2019 in the flavor enhancers market. Established key market players and continued investments from manufacturers are likely to drive market growth in North America during the forecast period.
- The key players in the market include Tate & Lyle PLC, Cargill, Corbion N.V., Associated British Foods plc, Sensient Technologies, ADM, Novozymes A/S, E.I. Dupont, Angel Yeast Co., Ltd, Innova Flavors, Savoury Systems International, Inc., Senomyx, Inc and Ajinomoto Co, Inc.
- In November 2019, Archer Daniels Midland Co. acquired Florida Chemical Company., which is specialized in citrus-based fragrances and flavors. Florida Chemical Co., a subsidiary of Flotek Industries based in Winter Haven. It offers citrus flavor materials and essential oils as well as flavor enhancers for grapefruit and other citruses.
BUY NOW (Customized Report Delivered as per Your Specific Requirement)@ https://www.reportsanddata.com/checkout-form/3408
For the purpose of this report, Reports and Data has segmented the Global Flavor Enhancers Market on the basis of type, application, source, form, and region:
Type Outlook (Revenue, USD Billion; 2017-2027)
- Hydrolyzed vegetable protein
- yeast extracts
- Others (sweetness enhancers and nucleotides)
Application Outlook (Revenue, USD Billion; 2017-2027)
- Processed & convenience foods
- Meat & fish products
- Confectionery products
Source Outlook (Revenue, USD Billion; 2017-2027)
Form Outlook (Revenue, USD Billion; 2017-2027)
- Liquid & semi-liquid
To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/flavor-enhancers-market
Regional Outlook (Revenue, USD Million; 2017-2027)
- North America
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Latin America
- Rest of LATAM
- Middle East & Africa
Take a Look at our Related Reports:
Isoflavones Market: https://www.reportsanddata.com/report-detail/isoflavones-market
Krill Oil Market: https://www.reportsanddata.com/report-detail/krill-oil-market
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.
Contact Us: John Watson Head of Business Development Reports And Data | Web: www.reportsanddata.com Direct Line: +1-212-710-1370 E-mail: firstname.lastname@example.org
Scipher Medicine and Galapagos sign collaboration in inflammatory bowel disease
— Companies to jointly validate novel drug targets —
— Scipher eligible for upfront, opt-in and milestone payments —
— Galapagos to progress selected targets into drug discovery —
Mechelen, Belgium and Boston, USA; 12 August 2020 – Galapagos NV (Euronext & Nasdaq: GLPG) and Scipher Medicine (Scipher), a Boston based privately held precision medicine company focused on autoimmune diseases, today announce a collaboration to advance novel drug targets identified by Scipher for the treatment of inflammatory bowel disease (IBD).
Scipher combines its proprietary Network Medicine Platform with molecular patient data and AI-based methods to identify novel targets and pathways in autoimmune diseases, including IBD.
Scipher and Galapagos will jointly validate a suite of novel IBD targets discovered by Scipher after which Galapagos has the exclusive option to progress up to five targets into further drug discovery and development. Under the terms of the agreement, Scipher is eligible to receive upfront, opt-in and milestone payments and Galapagos will retain the rights for the discovery, development and commercialization of therapeutics for the selected target(s).
“Our breakthrough approach combines extensive patient-level molecular data with AI methods to discover novel targets with the potential to treat specific groups of patients, including those not responding to therapies currently available,” said Alif Saleh, Chief Executive Officer of Scipher Medicine. “This partnership with Galapagos is a recognition of our innovative approach to discover and validate novel targets that could offer a solution for IBD patients.”
“The collaboration with Scipher is aligned with our strategy to discover and develop novel modes of action medicines with the potential to disrupt current treatment paradigms to address high unmet needs in inflammatory diseases,” said Piet Wigerinck, Chief Scientific Officer of Galapagos. “We believe that our drug discovery and development expertise alongside Scipher’s platform will support us in the discovery of exciting new drug candidates.”
About Scipher Medicine
Scipher Medicine, a precision immunology company, holds the fundamental belief that patients deserve simple answers to treatment options based on scientifically backed data. Leveraging our proprietary Network Medicine platform and artificial intelligence, we commercialize blood tests identifying a patient’s unique molecular disease signature and match such signature to most effective therapy ensuring patients receive optimal treatment from day one. The unprecedented amount of patient molecular data generated from our tests further drives development of novel and more effective therapeutics. We partner with payers, providers and pharma along the health care value chain to bring precision medicine to autoimmune diseases.
Galapagos NV discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises discovery through Phase 3 programs in inflammation, fibrosis, osteoarthritis and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.
Galapagos Forward-Looking Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks, uncertainties and other factors that could cause actual results to diﬀer materially from those referred to in the forward-looking statements and, therefore, the reader should not place undue reliance on them. These risks, uncertainties and other factors include, without limitation, the inherent uncertainties associated with target discovery and validation and drug discovery and development activities (including that data from the ongoing discovery activities may not support the validation of any novel IBD targets or the development of any IBD drug candidates with novel modes of action), expectations regarding the collaboration with Scipher, that Galapagos may decide not to exercise any option granted to it under the agreement with Scipher, and that Galapagos’ expectations regarding the further development of any potential future in-licensed program, including its potential to address a large unmet need in inflammatory diseases, may be incorrect, as well as those risks and uncertainties identified in our Annual Report on Form 20-F for the year ended December 31, 2019 and our subsequent filings with the SEC. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The forward-looking statements contained herein are based on management’s current expectations and beliefs and speak only as of the date hereof, and Galapagos makes no commitment to update or publicly release any revisions to forward-looking statements in order to reflect new information or subsequent events, circumstances or changes in expectations.
VP Investor Relations
+1 781 460 1784
Sofie Van Gijsel
Senior Director Investor Relations
+32 485 19 14 15
Head of Internal & External Communications & Public Affairs
+32 473 824 874
Senior Director Communications – Therapeutic Areas
+44 7717 801900
Media contacts Scipher Medicine:
OMNIQ Corp. to Host Second Quarter Earnings Call on Friday, August 14, 2020 at 11:00 AM ET
SALT LAKE CITY, Aug. 12, 2020 (GLOBE NEWSWIRE) — OMNIQ Corp. (OTCQB: OMQS) (“OMNIQ” or “the Company”), a provider of Supply Chain and Artificial Intelligence (AI)-based solutions, will host a conference call and webcast on Friday, August 14, 2020 at 11:00 a.m. Eastern Time to discuss financial results for the second quarter ended June 30, 2020.
To access the live webcast, please click on this webcast link to register, or go to the Company’s website at www.questsolution.com, and click on the About tab, then Investors.
To participate in the call by phone, dial (877) 407-9210 approximately five minutes prior to the scheduled start time. International callers please dial (201) 689-8049.
A replay of the teleconference will be available until September 13, 2020 and may be accessed by dialing (877) 481-4010. International callers may dial (919) 882-2331. Callers should use conference ID: 36627.
About OMNIQ Corp.
OMNIQ Corp. (OTCQB: OMQS) provides computerized and machine vision image processing solutions that use patented and proprietary AI technology to deliver data collection, real time surveillance and monitoring for supply chain management, homeland security, public safety, traffic & parking management and access control applications. The technology and services provided by the Company help clients move people, assets and data safely and securely through airports, warehouses, schools, national borders, and many other applications and environments. OMNIQ’s customers include government agencies and leading Fortune 500 companies from several sectors, including manufacturing, retail, distribution, food and beverage, transportation and logistics, healthcare, and oil, gas, and chemicals. Since 2014, annual revenues have grown to more than $50 million from clients in the USA and abroad. The Company currently addresses several billion-dollar markets, including the Global Safe City market, forecast to grow to $29 billion by 2022, and the Ticketless Safe Parking market, forecast to grow to $5.2 billion by 2023.
Information about Forward-Looking Statements
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995. Statements in this press release relating to plans, strategies, economic performance and trends, projections of results of specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. This release contains “forward-looking statements” that include information relating to future events and future financial and operating performance. The words “anticipate”, “may,” “would,” “will,” “expect,” “estimate,” “can,” “believe,” “potential” and similar expressions and variations thereof are intended to identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause these differences include, but are not limited to: fluctuations in demand for the Company’s products particularly during the current health crisis , the introduction of new products, the Company’s ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company’s liquidity and financial strength to support its growth, the Company’s ability to manage credit and debt structures from vendors, debt holders and secured lenders, the Company’s ability to successfully integrate its acquisitions, and other information that may be detailed from time-to-time in OMNIQ Corp.’s filings with the United States Securities and Exchange Commission. Examples of such forward looking statements in this release include, among others, statements regarding revenue growth, driving sales, operational and financial initiatives, cost reduction and profitability, and simplification of operations. For a more detailed description of the risk factors and uncertainties affecting OMNIQ Corp., please refer to the Company’s recent Securities and Exchange Commission filings, which are available at http://www.sec.gov. OMNIQ Corp. undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless otherwise required by law.
Latest News1 year ago
Bleckwen Raises $10m and Appoints David Christie as CEO
Artificial Intelligence1 year ago
Kneron Debuts Edge AI Chip, Bringing AI to Devices Everywhere
Artificial Intelligence5 months ago
Special Report: Coronavirus and the Housing Industry
Artificial Intelligence1 year ago
Chartis Research Names FICO a Category Leader in AI for Financial Services
Artificial Intelligence1 year ago
CredoLab extends smartphone-based scoring to insurers
Artificial Intelligence1 year ago
Tuya Exhibiting Products from its Global Clients that are “Powered by Tuya”
Artificial Intelligence1 year ago
LogRhythm Scores the Singapore Business Review Technology Excellence Award 2019 for Cyber Security – Computer Software
Artificial Intelligence1 year ago
Chengdu Tianfu Software Park Reflects the Vitality of IP Innovation